Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Revocation of closure direction for Company s Dahej site
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma has informed the stock exchanges that the closure direction previously issued against its Dahej manufacturing site has been revoked, under Regulation 30 disclosure norms. This means the site, which was earlier ordered to shut down or halt operations by a regulatory authority, has now been cleared to resume normal operations. The Dahej facility is one of Piramal Pharma's key manufacturing locations contributing to its pharma and contract development businesses. Specific reasons for the revocation or the timeline for resumption of operations have not been detailed in this disclosure.
Positive for shareholders as it removes a major operational and revenue risk from the Dahej plant, allowing production and supplies to restart and easing concerns about compliance issues and potential business disruption.